Register for our free email digests:
Prothena Corporation plc
https://www.prothena.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Prothena Corporation plc
Prothena Gives Amyloidosis Drug Birtamimab A Second Chance
With post hoc analysis from a 2018 study showing a survival benefit in patients at high risk for early mortality, Prothena negotiated a path forward with the US FDA for approval in AL amyloidosis.
Prothena Sees Potential In Targeting Amyloid, Validated By Biogen
Prothena views potential approval of Biogen’s aducanumab as a flag in the sand for next-generation amyloid-targeting therapies to race past, including the firm’s own antibody and vaccine programs.
Roche's pRED Leaders On Its Next Generation Of Drugs
"We're not resting on our laurels," pRED head William Pao said in an early R&D overview. The company's R&D leaders highlighted drugs in oncology, neuroscience and ophthalmology.
Finance Watch: VC Mega-Deals Launch Biopharma Firms With New Takes On CV, Genetic Diseases
Anthos premiers with $250m from Blackstone and cardiovascular disease assets and expertise from Novartis, while Maze brings in $191m for drugs that target gene modifiers. In public company financings, Sage raises $575m ahead of Zulresso approval decision.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Neotope Biosciences Limited